NIH Locks Doors for Secret Science Grant Huddles
Published Date: 9/24/2025
Notice
Summary
The Center for Scientific Review is holding several closed virtual meetings in November 2025 to review important grant applications. These meetings protect private info and trade secrets while deciding who gets funding for health and science projects. Researchers and small businesses applying for grants should note these dates as they impact funding decisions.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 0 costs, 1 mixed.
Small Business Grant Panels on Nov 18-19
Several Small Business review panels (including Innovations for Healthy Living; Cell and Molecular Biology; Sensory Technologies) will meet virtually on November 18 and November 18-19, 2025 to review and evaluate grant applications. If you are a small business applying to these topic panels, your application will be reviewed on those dates and may affect whether you receive NIH funding.
Career Development and Mentored Award Reviews
Career development and mentored/career transition award panels (for example: Career Development Award Grant Review: Aging and Mental Health; Mentored and Career Transition Award) will meet virtually on November 18, 2025 to review grant applications. If you are a researcher applying for these awards, your application will be evaluated on that date and could affect your chances for career-support funding.
Meetings Closed to Protect Applicant Privacy
The NIH Center for Scientific Review will close listed review meetings to the public under 5 U.S.C. 552b(c)(4) and 552b(c)(6) because grant discussions could reveal confidential trade secrets or personal information. These closed virtual meetings on November 18 and November 18-19, 2025 mean applicant trade secrets and personal details are protected, but the public cannot observe the reviews.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
Previous / Next Documents
Previous: 2025-18511, Information Collections Being Submitted for Review and Approval to Office of Management and Budget
The FCC is asking everyone, especially small businesses with fewer than 25 employees, to share ideas on how to make paperwork easier and less time-consuming. They want to make sure all info collections have proper approval and no one gets penalized unfairly. This is a chance to help cut red tape and improve how the FCC collects info, with deadlines coming soon.
Next: 2025-18513, Notice of Public Meeting of the Georgia Advisory Committee to the U.S. Commission on Civil Rights
The Georgia Advisory Committee to the U.S. Commission on Civil Rights is holding a public Zoom meeting to review the first draft of their civil rights proposal. This meeting affects anyone interested in civil rights progress in Georgia and invites public attention before final decisions. No money changes are involved, but the timing is key to shaping future civil rights actions.